today surpris decis file aducanumab earli stunner us mani
investor especi futil analysi march thought engage/
emerg data interest far unequivoc regul like rais
signific question aducanumab efficaci given diverg outcom
emerg engag inconsist dose respons engag treatment
endpoint wors placebo initi neg futil analysi biogen
maintain explain result protocol amend analysi
differ dose interv time point complet understand unmet
medic need alzheim view fda like relax approv
criteria two posit pivot studi primari endpoint mix
approv packag would set bad industri preced potenti offer million
patient fals hope unproven therapi inde partner eisai
compel initi phase ad posit trend still
mix phase data think logic path forward pivot studi
high-dos aducanumab pre post approv set next event ctad dec
san diego kol feedback critic investor follow
bla file expect much way data point beyond bla accept
like fda advisori panel mid fulli expect aducanumab domin
discuss regardless potenti ipr settlement tecfidera
competit dynam ms sma pipelin develop
commerci headwind remain rais po option
report modestli posit result top-lin bottom-lin
core franchis multipl sclerosi spinraza ahead larg due ou trend
remain durabl increas sign competit pressures
tecfidera tysabri stabil us rx trend grow use zolgensmaw continu
see declin growth revenu earn compound-annual-growth-rate vs large-cap
closer peer vs continu cautiou name reiter
under-perform rate increas po ad pipelin option
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
global biotechnolog compani
develop manufactur market therapi
multipl sclerosi oncolog inflammatori
tysabri tecfidera combin
consider share world-wide
rate under-perform given
concern posit compani
commerci portfolio ms franchis
spinraza face meaning commerci
headwind pipelin focus early-
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
follow earn result adjust model reflect updat trend
commentari forecast total revenu
vs prior result estim
non-gaap ep vs prior exhibit
exhibit updat model
million ex per share item
million ex per share item
net incom non-gaap
price object base sum-of-th part npv analysi forecast sale
key product use wacc termin valu
assumpt valu entir ms franchis spinraza
collabor revenu biosimilar pipelin
net cash net po
upsid risk po better expect sale tecfidera less eros
avonex plegridi tysabri anticip vumer meaning captur
market share strong durabl spinraza success number early-stag
pipelin program result acceler approv develop
downsid risk greater expect moder ms sale avonex plegridi
tysabri due increas competit rapid eros spinraza market share
sma limit success pipelin mani product fail advanc
approv narrow indic smaller patient popul
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
